Sarepta Therapeutics Inc. (NASDAQ:SRPT) had its price target increased by equities researchers at Needham & Company LLC from $47.00 to $81.00 in a research note issued on Wednesday. The firm currently has a “buy” rating on the stock. Needham & Company LLC’s price objective would indicate a potential upside of 44.08% from the stock’s previous close.

SRPT has been the topic of a number of other research reports. JMP Securities reissued a “sell” rating and issued a $10.00 target price on shares of Sarepta Therapeutics in a report on Friday, June 3rd. Cowen and Company reissued a “hold” rating on shares of Sarepta Therapeutics in a report on Tuesday, June 7th. Janney Montgomery Scott reissued a “hold” rating on shares of Sarepta Therapeutics in a report on Tuesday, June 7th. Robert W. Baird reissued an “outperform” rating and issued a $23.00 target price on shares of Sarepta Therapeutics in a report on Friday, June 3rd. Finally, Piper Jaffray Cos. reissued a “sell” rating and issued a $6.00 target price on shares of Sarepta Therapeutics in a report on Saturday, June 4th. Two analysts have rated the stock with a sell rating, four have given a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $51.01.

Shares of Sarepta Therapeutics (NASDAQ:SRPT) traded up 0.88% during trading on Wednesday, reaching $56.22. 8,767,424 shares of the company traded hands. The company has a 50-day moving average of $29.05 and a 200-day moving average of $21.62. Sarepta Therapeutics has a 12 month low of $8.00 and a 12 month high of $58.87. The stock’s market capitalization is $2.69 billion.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/14/sarepta-therapeutics-inc-srpt-pt-raised-to-47-00-at-needham-company-llc.html

Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings results on Tuesday, July 19th. The company reported ($1.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.19) by $0.16. During the same quarter in the previous year, the company earned ($0.87) earnings per share. Analysts forecast that Sarepta Therapeutics will post ($4.17) earnings per share for the current fiscal year.

In other news, VP Jayant Aphale sold 35,000 shares of Sarepta Therapeutics stock in a transaction on Monday, September 19th. The stock was sold at an average price of $50.00, for a total value of $1,750,000.00. Following the transaction, the vice president now directly owns 21,490 shares in the company, valued at approximately $1,074,500. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Edward M. Md Kaye sold 24,557 shares of Sarepta Therapeutics stock in a transaction on Wednesday, September 14th. The shares were sold at an average price of $30.00, for a total value of $736,710.00. Following the completion of the transaction, the chief executive officer now owns 76,983 shares in the company, valued at $2,309,490. The disclosure for this sale can be found here. Company insiders own 10.90% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. American Century Companies Inc. bought a new position in shares of Sarepta Therapeutics during the second quarter worth about $651,000. Eagle Asset Management Inc. bought a new position in shares of Sarepta Therapeutics during the second quarter worth about $6,756,000. Amici Capital LLC bought a new position in shares of Sarepta Therapeutics during the first quarter worth about $488,000. LGL Partners LLC increased its position in shares of Sarepta Therapeutics by 4.2% in the first quarter. LGL Partners LLC now owns 24,862 shares of the company’s stock worth $485,000 after buying an additional 1,000 shares in the last quarter. Finally, A.R.T. Advisors LLC bought a new position in shares of Sarepta Therapeutics during the first quarter worth about $7,461,000. Institutional investors and hedge funds own 72.09% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.

5 Day Chart for NASDAQ:SRPT

Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.